Women's Health Policy

ABORTION IN THE U.S.

KFF infographic explaining who regulates mifepristone, showing four entities and their roles: the U.S. Food and Drug Administration approves and regulates medications for safety and effectiveness; state legislatures pass laws that can restrict or protect access; courts rule on legal cases affecting regulation; and Congress can pass federal legislation influencing regulation.

Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

Louisiana sued the FDA in October 2025, claiming the FDA’s 2023 regulatory change eliminating the requirement that mifepristone be dispensed in-person—allowing it to be mailed or dispensed at retail pharmacies—harm the state's ability to enforce its abortion ban. This brief reviews the Louisiana v. FDA case and provides an overview of the other pending litigation involving mifepristone, as well as the mounting tension between states seeking to protect abortion and those banning the provision of abortion.

CONTRACEPTIve care IN THE U.S.

An Update on Medicaid, Title X and Planned Parenthood

This brief provides an update on Planned Parenthood clinic closures and participation in the Title X program amid substantial policy changes resulting in funding reductions. These changes include the One Big Beautiful Bill Act and the withholding of federal Title X funding to Planned Parenthood clinics.

SELECTED RESOURCES

Over-the-Counter Oral Contraceptive Pills

In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Stay informed.

Stay informed.

Filter

241 - 250 of 874 Results

  • Update on the Status of Medication Abortion and the Courts

    Policy Watch

    This policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.

  • After Dobbs, Survey Seeks to Understand Telecontraception Clients Better

    News Release

    According to a new KFF survey with a nonprobability sample of clients from four online sources of contraception, one in four clients said they got emergency contraception to have on hand because of the Supreme Court’s decision to overturn Roe v. Wade. Additionally, more than a fifth (22%) said they have considered sterilization, 12% reported that they considered switching to or started using a more effective method of birth control, and eight percent said that…

  • As the Courts Weigh the Future of the ACA’s Preventive Services Coverage, a New Analysis Shows that Most People with Private Insurance Received At Least One of Those Benefits in 2018

    News Release

    The provision of the Affordable Care Act (ACA) that requires most private health plans to cover many preventive services without any cost-sharing for their enrollees is being challenged in federal court. The U.S. District Court in the Northern District of Texas in September concluded that aspects of the requirement were unconstitutional and violated religious rights but has allowed the provision to remain in effect while it considers a remedy. As the courts consider the ACA’s…

  • Challenges to the FDA’s Approval of Medication Abortion Pills Could Curtail Access Throughout the United States

    News Release

    In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most attention recently is Alliance for Hippocratic Medicine (AHM) v. FDA, filed in November 2022, a challenge to the FDA’s decision to approve mifepristone (the first…

  • Legal Challenges to the FDA Approval of Medication Abortion Pills

    Issue Brief

    This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA's approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.

  • Medication Abortion in the Courts: What’s at Stake?

    News Release

    Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000, has a long record of safety and effectiveness and has been used by more than 5 million people in the United States. In the most…

  • 2022 Women’s Health Survey

    Feature

    The 2022 KFF Women’s Health Survey is part of a series of nationally representative surveys on women’s health conducted by KFF periodically since 2001. The survey’s objective is to better understand women’s experiences with contraception, access to health care, and other issues related to health and well-being.

  • New KFF Trackers Document State and Federal Reproductive Rights Litigation Across the Country

    News Release

    KFF has created two new trackers to follow swift-moving reproductive rights litigation in the state and federal courts. The tools, which are currently tracking the status of 21 state cases in 15 states and eight federal cases, will be updated regularly as the litigation proceeds. Major cases pending in federal and state courts could impact access to abortion and contraceptive care for millions across the US. In fact, a federal district court is considering a…